Regional analysis of a cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz plus P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with doce
Data de publicación
2014Título da revista
Journal Of Clinical Oncology
Tipo de contido
Publicación de congreso